{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:32:13Z","timestamp":1760574733655,"version":"build-2065373602"},"reference-count":25,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T00:00:00Z","timestamp":1759795200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Background: Clonazepam is a benzodiazepine drug indicated in all clinical forms of epileptic seizures, various forms of myoclonic seizures, myoclonus and other abnormal movements. At present, it is classified as a hazardous drug requiring special precautions for personnel at reproductive risk, according to a technical document produced by the Spanish National Institute for Safety and Health at Work (INSST), in collaboration with the Spanish Society of Hospital Pharmacy (SEFH). The commercial solutions of clonazepam, for oral and parenteral administration, are supplied by laboratories in glass containers. Repacking in pre-filled polypropylene (PP) syringes, made in the pharmacy service, and in aseptic conditions, may facilitate its administration and reduce the risks to the health or safety of nursing personnel. Nevertheless, there is a lack of stability studies of clonazepam in pre-filled PP syringes. Objectives: To evaluate the physicochemical stability of commercial clonazepam 2.5 mg\/mL oral solution and 1 mg\/mL parenteral solution repackaged in pre-filled PP syringes under various storage conditions. Methods: A rapid, linear, precise and sensitive high-performance liquid chromatography (HPLC) method for chemical stability studies of Clonazepam 1 mg\/mL (parenteral use) and 2.5 mg\/mL (oral use) in solution was implemented after repackaging in pre-filled PP syringes. The studies were conducted by measuring concentrations of oral and parenteral clonazepam in pre-filled syringes, at various time points, over 30 days in several different storage conditions: oral clonazepam protected from light in refrigerator and at controlled room temperature exposed to ambient light; parenteral clonazepam protected from light in a refrigerator and at controlled room temperature protected or unprotected from light. Visual aspects and pH change as well as crystal formation were checked to determine physical stability. Results: The degradation of the active ingredient in all groups was less than 10% after 30 days. No evidence of crystal formation, pH and visual aspect changes were observed. Conclusions: Clonazepam 1 mg\/mL parenteral solution and 2.5 mg\/mL oral solution in pre-filled PP syringes are stable for up to 30 days in the tested conditions. The centralized repackaging of clonazepam in pre-filled PP syringes, connected to a closed safety system, in the pharmacy service, reduces drug manipulation by nursing staff decreasing the risk of occupational exposure.<\/jats:p>","DOI":"10.3390\/pharmaceutics17101302","type":"journal-article","created":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T10:48:07Z","timestamp":1759834087000},"page":"1302","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stability Studies of Clonazepam 2.5 mg\/mL Oral Solution and 1 mg\/mL Parenteral Solution in Pre-Filled Polypropylene Syringes"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4247-8942","authenticated-orcid":false,"given":"Juan Carlos","family":"Ruiz Ramirez","sequence":"first","affiliation":[{"name":"Deparment of Pharmacology, Faculty of Pharmacy, University of Murcia, 30003 Murcia, Spain"},{"name":"Pharmacy Service, Los Arcos del Mar Menor General University Hospital, Murcian Health Service, 30739 Murcia, Spain"},{"name":"Biomedical Research Institute of Murcia Pascual Parrilla\u2014IMIB, 30120 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Icram","family":"Talsi Hamdani","sequence":"additional","affiliation":[{"name":"Deparment of Pharmacology, Faculty of Pharmacy, University of Murcia, 30003 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Berm\u00fadez Gazquez","sequence":"additional","affiliation":[{"name":"Deparment of Pharmacology, Faculty of Pharmacy, University of Murcia, 30003 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alice Charlotte","family":"Viney","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Los Arcos del Mar Menor General University Hospital, Murcian Health Service, 30739 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-7520-1132","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Alonso Herreros","sequence":"additional","affiliation":[{"name":"Deparment of Pharmacology, Faculty of Pharmacy, University of Murcia, 30003 Murcia, Spain"},{"name":"Pharmacy Service, Los Arcos del Mar Menor General University Hospital, Murcian Health Service, 30739 Murcia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"ref_1","unstructured":"(2024, August 12). Spanish Medicines and Medical Devices Agency Datasheet of Rivotril 1 mg\/mL Concentrate and Solvent for Injectable Solution. Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/52332\/FT_52332.html."},{"key":"ref_2","unstructured":"(2024, August 12). Spanish Medicines and Medical Devices Agency Datasheet of Rivotril 2.5 mg\/mL Oral Drops Solution. Available online: https:\/\/cima.aemps.es\/cima\/dochtml\/ft\/52333\/FT_52333.html#5-propiedades-farmacol-gicas."},{"key":"ref_3","unstructured":"National Institute for Occupational Safety and Health Hazardous Drugs (2024, August 12). Preventive Measures for Their Preparation and Administration. Available online: https:\/\/www.insst.es\/documentacion\/catalogo-de-publicaciones\/medicamentos-peligrosos.-medidas-de-prevencion-para-su-preparacion-y-administracion."},{"key":"ref_4","unstructured":"Connor, T.H., MacKenzie, B.A., DeBord, D.G., Trout, D.B., O\u2019Callaghan, J.P., Ovesen, J.L., Whittaker, C., Cincinnati, O.H., and National Institute for Occupational Safety and Health NIOSH [2020] (2024, August 05). NIOSH List of Hazardous Drugs in Healthcare Settings 2020, Available online: https:\/\/www.cdc.gov\/niosh\/docket\/review\/docket233c\/pdfs\/DRAFT-NIOSH-Hazardous-Drugs-List-2020.pdf."},{"key":"ref_5","unstructured":"Lal, R. (2024, August 27). Drugs in Pregnancy and Lactation: Improved Benefit-Risk Information 2015, Available online: https:\/\/www.fda.gov\/files\/drugs\/published\/%22Drugs-in-Pregnancy-and-Lactation--Improved-Benefit-Risk-Information%22-January-22--2015-Issue.pdf."},{"key":"ref_6","first-page":"27","article-title":"Oxygen Permeability in Food Packaging made of Polypropylene by Injection Moldin","volume":"53","year":"2024","journal-title":"Rev. Polit\u00e9cnica"},{"key":"ref_7","first-page":"587","article-title":"Interacci\u00f3n de f\u00e1rmacos y mezclas parenterales con productos sanitarios","volume":"11","year":"2020","journal-title":"Panor. Actual Del Medicam."},{"key":"ref_8","unstructured":"Laboratorios Grifols, S.A. (2024, October 09). Estabilidad y Compatibilidad de Medicamentos. Available online: https:\/\/gruposdetrabajo.sefh.es\/gps\/images\/stories\/descargas\/Compatibilidad_medicamentos_diluyentes.pdf."},{"key":"ref_9","unstructured":"European Directorate for the Quality of Medicines & HealthCare (2022). European Pharmacopoeia, European Directorate for the Quality of Medicines & HealthCare. [11th ed.]."},{"key":"ref_10","unstructured":"Tietje, C., and Brouder, A. (2010). Stability Testing of New Drug Sjustances and Products Q1A(R2). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, Brill|Nijhoff."},{"key":"ref_11","unstructured":"Troy, D.B., and Beringer, P. (2006). Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins."},{"key":"ref_12","unstructured":"Spanish Agency of Medicines and Medical Devices Visible Particle Contamination (2024, September 10). Spanish Royal Pharmacopoeia Online. Available online: https:\/\/extranet.boe.es\/farmacopea\/doc.php?id=20920."},{"key":"ref_13","first-page":"175","article-title":"The stability of medicines in the clinical practice. From safety to efficiency","volume":"37","author":"Barrueco","year":"2013","journal-title":"Farm. Hosp."},{"key":"ref_14","unstructured":"United States Pharmacopeial Convention (2022). United States Pharmacopeia and National Formulary (USP-NF), US Pharmacopeia Convention, Inc.. [2022nd ed.]."},{"key":"ref_15","unstructured":"Guchelaar, H.J., and Hartog, M.E. (2025, August 11). De Stabiliteit van Clonazepaminjectievloeistof. Available online: https:\/\/www.stabilis.org\/Bibliographie.php?IdBiblio=2217."},{"key":"ref_16","unstructured":"Castro, M., Gasc\u00f3n, S., Pujol, M., Sans, J., and Vicente, L. (1989). Validation of Analytical Methods. Monograph. Commission on Good Manufacturing Practice and Quality Control Standards, Spanish Association of Industrial Pharmacists (AEFI)."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1093\/ajhp\/53.16.1944","article-title":"Stability of acetazolamide, allopurinol, azathioprine, clonazepam, and flucytosine in extemporaneously compounded oral liquids","volume":"53","author":"Allen","year":"1996","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_18","first-page":"167","article-title":"Stability of Atenolol, Clonazepam, Dexamethasone, Diclofenac Sodium, Diltiazem, Enalapril Maleate, Ketoprofen, Lamotrigine, Penicillamine-D, and Thiamine in SyrSpend SF PH4 Oral Suspensions","volume":"20","author":"Polonini","year":"2016","journal-title":"Int. J. Pharm. Compd."},{"key":"ref_19","unstructured":"Brouder, A., and Tietje, C. (2009). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. Handbook of Transnational Economic Governance Regimes, Brill."},{"key":"ref_20","first-page":"2","article-title":"A Validated Stability\u2013Indicating HPLC Method estimation of Clonazepam In the bulk drug and Pharmaceutical Dosage Form","volume":"6","year":"2015","journal-title":"Pharm. Anal. Acta"},{"key":"ref_21","unstructured":"Hoffman, F. (1987). Statistical Validation: Quantitative determination (General Explanations), La Roche."},{"key":"ref_22","unstructured":"Miller, J., and Miller, J.C. (2005). Statistics and Chemometrics for Analytical Chemistry, Pearson Education Limited."},{"key":"ref_23","unstructured":"(2024, August 28). European Agency for Safety and Health at Work Guidance for the Safe Management of Hazardous Medicinal Products at Work | Safety and Health at Work EU-OSHA 2023. Available online: https:\/\/osha.europa.eu\/en\/publications\/guidance-safe-management-hazardous-medicinal-products-work."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"135","DOI":"10.59551\/IJHMP\/25832069\/2025.6.1.117","article-title":"Comprehensive stability evaluation and shelf -life determination of escitalopram and clonaepam fixed-dose combination tablets","volume":"6","author":"Shaarma","year":"2025","journal-title":"IJHMP"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.5740\/jaoacint.10-083","article-title":"Stability studies of clonazepam, diazepam, haloperidol, and doxepin with diverse polarities in an acidic environment","volume":"94","author":"Krzek","year":"2011","journal-title":"J. AOAC Int."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1302\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T08:59:37Z","timestamp":1760518777000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/17\/10\/1302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,7]]},"references-count":25,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["pharmaceutics17101302"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics17101302","relation":{},"ISSN":["1999-4923"],"issn-type":[{"type":"electronic","value":"1999-4923"}],"subject":[],"published":{"date-parts":[[2025,10,7]]}}}